<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215511</url>
  </required_header>
  <id_info>
    <org_study_id>20810</org_study_id>
    <secondary_id>LOXO-EXT-17005</secondary_id>
    <secondary_id>2017-004246-20</secondary_id>
    <nct_id>NCT03215511</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer</brief_title>
  <official_title>A Phase 1/2 Study of the TRK Inhibitor Selitrectinib in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is done to test the safety of the new drug selitrectinib in children and&#xD;
      adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may&#xD;
      treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study&#xD;
      also investigates how the drug is absorbed and processed in the human body, and how well and&#xD;
      for how long the cancer responds to the drug. This is the first study to test selitrectinib&#xD;
      in humans with cancer, for whom no other effective therapy exists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in 2 parts: dose escalation and expansion (Phase 1) and Phase 2.&#xD;
&#xD;
      The primary objective of Phase 1 is to establish the recommended dose of selitrectinib to&#xD;
      treat neurotrophic tyrosine kinase (NTRK) fusion cancers in patients a) aged 12 years and&#xD;
      older and b) younger than 12 years. Secondary objectives of Phase 1 are to characterize the&#xD;
      pharmakokinetic properties of the test drug, its safety and tolerability, and to assess the&#xD;
      objective response rate (ORR) of NTRK-tumors.&#xD;
&#xD;
      The primary objective of Phase 2 is to assess the overall response rate in NTRK fusion cancer&#xD;
      patients as determined by an independent radiology committee (IRR). Secondary objectives of&#xD;
      Phase 2 comprise the safety and efficacy of selitrectinib at the recommended dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">July 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Recommended dose</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate (ORR) for patients &lt;12 years from Cohort 1 by IRR</measure>
    <time_frame>Up to 40 months</time_frame>
    <description>ORR is determined by an Independent Radiology Committee (IRR) using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate (ORR) for patient ≥12 years from Cohort 1 by IRR</measure>
    <time_frame>Up to 40 months</time_frame>
    <description>ORR is determined by an Independent Radiology Committee (IRR) using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Incidence of adverse events</measure>
    <time_frame>Up to 56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Severity of adverse events</measure>
    <time_frame>Up to 56 months</time_frame>
    <description>Severity is assessed using CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Duration of adverse events</measure>
    <time_frame>Up to 56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration</measure>
    <time_frame>Up to 56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Severity of safety-relevant changes in clinical parameters or vital signs after drug administration</measure>
    <time_frame>Up to 56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response rate (ORR) in patients with NTRK fusion cancer previously treated with TRK inhibitor determined by investigator</measure>
    <time_frame>Up to 56 months</time_frame>
    <description>ORR is determined by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response rate (ORR) in patients with primary central nervous system (CNS) malignancies determined by investigator</measure>
    <time_frame>Up to 56 months</time_frame>
    <description>ORR is determined by the treating investigator using the Response Assessment in Neuro-Oncology (RANO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall survival (OS)</measure>
    <time_frame>Up to 56 months</time_frame>
    <description>Number of months from the initiation of selitrectinib to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum concentration of BAY2731954 in plasma (Cmax)</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 1, predose, 0.5, 1, 2, 4 post-dose on Day 8 of Cycle 1 (cycle length 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area under the concentration versus time curve of BAY2731954 in plasma (AUC(0-last))</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 5, 8 and 10 hours post-dose on Days 1, 8, 15 and 22 of Cycle 1 (cycle length 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Incidence of adverse events in patients ≥12 years</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Severity of adverse events in patients ≥12 years</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>Severity is assessed using CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of adverse events in patients ≥12 years</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Incidence of adverse events in patients &lt;12 years</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Severity of adverse events in patients &lt;12 years</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>Severity is assessed using CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of adverse events in patients &lt;12 years</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Severity of safety-relevant changes in clinical parameters or vital signs after drug administration</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall response rate (ORR) in Cohort 2 determined by IRR</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>ORR is determined by an Independent Radiology Committee (IRR) using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall response rate (ORR) determined by investigator</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>ORR is determined by the treating investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or the Response Assessment in Neuro-Oncology (RANO) criteria, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of response (DOR) determined by IRR</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>Determined by an Independent Radiology Committee (IRR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of response (DOR) determined by investigator</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival (PFS) determined by IRR</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>Determined by an Independent Radiology Committee (IRR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival (PFS) determined by investigator</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall survival (OS)</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Clinical benefit rate (CBR) determined by IRR</measure>
    <time_frame>Up to 44 months</time_frame>
    <description>Determined by an Independent Radiology Committee (IRR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Clinical benefit rate (CBR) determined by investigator</measure>
    <time_frame>Up to 44 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Solid Tumors Harboring NTRK Fusion</condition>
  <arm_group>
    <arm_group_label>Phase 1: Cancer patients &lt;12 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts with pediatric patients aged &lt;12 years. Dose escalation starts with 43 mg of selitrectinib per m2 body surface twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Cancer patients ≥12 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts with patients aged 12 years or older. Dose escalation starts with 100 mg of selitrectinib twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cancer patients_Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort consisting of patients with NTRK fusion cancers showing disease progression despite treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cancer patients_Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort consisting of patients with NTRK fusion cancers showing intolerance or unresponsiveness to previous treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selitrectinib (BAY2731954)</intervention_name>
    <description>Selitrectinib is administered as capsules or liquid formulation.</description>
    <arm_group_label>Phase 1: Cancer patients &lt;12 years</arm_group_label>
    <arm_group_label>Phase 1: Cancer patients ≥12 years</arm_group_label>
    <arm_group_label>Phase 2: Cancer patients_Cohort 1</arm_group_label>
    <arm_group_label>Phase 2: Cancer patients_Cohort 2</arm_group_label>
    <other_name>Loxo-195</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced solid tumor for which, in the opinion of the investigator, no other standard&#xD;
             therapy offers greater benefit.&#xD;
&#xD;
          -  A solid tumor diagnosis in the setting of:&#xD;
&#xD;
               -  a) a documented NTRK fusion and a clinical history of relapse following a&#xD;
                  response to a prior TRK inhibitor&#xD;
&#xD;
               -  b) a documented NTRK fusion unresponsive to a prior TRK inhibitor&#xD;
&#xD;
               -  c) a documented NTRK fusion and a clinical history of intolerance to a prior TRK&#xD;
                  inhibitor&#xD;
&#xD;
          -  NTRK gene fusions will be identified in a CLIA-certified (or equivalently-accredited&#xD;
             diagnostic) laboratory. If such a report cannot be provided, other available&#xD;
             certifications/accreditations are required and need to be documented. Patients with&#xD;
             infantile fibrosarcoma (IFS) or congenital mesoblastic nephroma (CMN) may be enrolled&#xD;
             based on an ETV6+ FISH test without identifying NTRK3.&#xD;
&#xD;
          -  Performance Status: Eastern Cooperative Oncology Group (ECOG) score ≤ 2 in adults or&#xD;
             Karnofsky Performance Score (KPS) Score≥50% (age ≥ 16 years) or Lansky Performance&#xD;
             Score (LPS) ≥ 40% (age &lt; 16 years).&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function.&#xD;
&#xD;
          -  Patients with stable central nervous system (CNS) primary tumor, brain metastases, or&#xD;
             treated spinal cord compression are eligible if neurological symptoms have been stable&#xD;
             for 7 days prior to the first dose of selitrectinib.&#xD;
&#xD;
          -  Ability to receive study drug orally or by enteral administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to second generation TRK inhibitor (e.g. selitrectinib, repotrectinib&#xD;
             (TPX-0005)), taletrectinib (DS-6501b/AB-106)). Exception is in case patient presented&#xD;
             intolerance to the second generation TRK inhibitor agent and the duration of exposure&#xD;
             was less than 28 days. No previous treatment with selitrectinib is allowed.&#xD;
&#xD;
          -  Concurrent treatment with a strong CYP3A4 inhibitor or inducer, consumption of&#xD;
             grapefruit juice or Seville oranges, or drugs associated with QT prolongation.&#xD;
&#xD;
          -  Clinically significant active cardiovascular disease or history of myocardial&#xD;
             infarction within 3 months prior to planned start of selitrectinib, or prolongation of&#xD;
             QT interval corrected for heart rate (QTc interval) &gt;480 milliseconds within past 6&#xD;
             months&#xD;
&#xD;
          -  Major surgery within 7 days of enrollment&#xD;
&#xD;
          -  Uncontrolled systemic bacterial, fungal or viral infection.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Known hypersensitivity to selitrectinib or Ora-Sweet® SF and OraPlus® for patients&#xD;
             receiving liquid formulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ.of California-San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finsen Centre</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Ulm - Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallaght Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitària i Universitaria de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz (Clinica de la Concepcion)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Metastatic cancer</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Neurotrophic tyrosine receptor kinase (NTRK)</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>Fusion Positive</keyword>
  <keyword>Children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selitrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

